DOCSLIB.ORG

Marketing Fragment 8.5 X 12.T65

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Marketing Fragment 8.5 X 12.T65 Cambridge University Press 978-0-521-85657-7 - Liver Disease in Children, Third Edition Edited by Frederick J. Suchy, Ronald J. Sokol, and William F. Balistreri Index More information I NDEX Page numbers followed by “f ” indicate figures, and those followed by “t ” indicate tables. ABCB11 gene. See BSEP gene and fulminant hepatic failure, 977 definition of, 71 ABO incompatibility in tyrosinemia, 707 etiology of, 72t, 72–79, 73t bilirubin production and, 279 acetylsalicylic acid (aspirin). See aspirin autoimmune hepatitis, 76, 77f liver transplantation and, 981 acid α-glucosidase (GAA), 725 drug and toxin related, 72–75, 485 abscesses acid-base disturbances, 87, 89 hepatitis viruses, 75–76 from Entamoeba histolytica, 880–881, acid ceramidase (ASAH), 720 indeterminate causes, 78f, 78–79 881f acid sphingomyelinase deficiency, 719f, infectious diseases, 75 pyogenic, 871–873, 872f 719–720 inherited and metabolic, 77 acalculous cholecystitis, 349–350 acquired immunodeficiency syndrome ischemia and abnormal perfusion, clinical features of, 349–350, 350f (AIDS), 240–241 77–78 etiology and pathogenesis of, 349, 349t Actinomyces israelli, 877–878 malignancy and infiltrative disorders, other acalculous entities of, 351 actinomycosis, 877–878 78 acalculous gallbladder disease, 347 acute fatty liver of pregnancy (AFLP), 781 miscellaneous diseases, 78 acanthosis nigricans, in nonalcoholic fatty acute liver failure and, 78 non-hepatitis viruses, 76 liver disease, 831 vs. HELLP syndrome, 781–782 nonviral hepatitis, 76 accumulation theory of liver injury in and maternal liver disease and LCHAD frequency of, 71 α1-antitrypsin deficiency, 556 deficiency, 782t, 782–783 immunologic disturbances and, 514 acetaminophen metabolites in, 816 management of, 89–91 N-acetylcysteine (NAC) therapy for, 90 acute intermittent porphyria (AIP), general measures, 89–90 in acute liver failure, 80f 682–684. See also porphyria(s) therapies, 90–91 acute liver failure and, 74 classification of, 680, 680t outcomes and prognosis, 91–92 and acute liver failure in children, 485 clinical features of, 682–683 causes of death, 91 and alcohol, 486 diagnosis of, 683–684 indicators of outcome, 91 elimination half-life of, 486 drugs that may be harmful in, 682, 683t model for, 91–92 in Gilbert’s syndrome, 290–291 homozygous dominant, 684t, 684–685 and onset of complications, 91 hepatotoxicity and metabolism of, treatment of, 684 from PALF study, 73t,91 484–487, 485f acute liver failure (ALF) in children, 71–92 overview of, 71 outcomes for overdose, 91 complications of, 82–89 pathogenesis of, 80–82 and tumor risk, 944 aplastic anemia, 86 exposure, 80–81 N-acetyl glutamate synthetase (NAGS), 862 ascites, 87 hepatocyte injury, 81 N-acetyl-L-cysteine, for veno-occlusive cardiovascular and pulmonary, 88 potentiation, 81–82 disease, 903 cerebral edema, 84–85 regeneration, 82 N-acetyl-p-aminophenol (APAP). See coagulopathy and hemorrhage, 85–86 pathology and biochemistry of, 79–80 acetaminophen electrolyte and acid-base disturbances, aminotransferase levels, 79–80, 80f N-acetyl-p-benzoquinoneimine (NAPQI), 87 bilirubin levels, 80 in acetaminophen metabolism, encephalopathy, 82–84, 83t biopsy, 79, 79f,80f,81f 485–486 hypoglycemia, 86 presentation of, 82 N-acetyl transferase 2 (NAT2), 19 pancreatitis, 87 acute phase response (APR), and liver N-acetylcysteine (NAC), 90 renal dysfunction, 87 infection, 31 in acetaminophen toxicity, 484–486 secondary infections, 88–89 acute phase response to infection, 897 995 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-85657-7 - Liver Disease in Children, Third Edition Edited by Frederick J. Suchy, Ronald J. Sokol, and William F. Balistreri Index More information 996 ■ I NDEX acute vanishing bile duct syndrome, bile duct-to-portal tract (BD/PT) ratio infusions and paracentesis, 113 985–986 in, 45, 327 as liver specific marker, 3 acyclovir, 236, 428, 986–987 clinical features and complications of, tests for, 107, 168 acyl-CoA oxidase deficiency, 850 327f, 329–339 aldose reductase inhibitors, in galactosemia acylcarnitine. See also carnitine cardiac, 332f, 332–333, 333f treatment, 599 fatty acid oxidation and, 538–539 facial, 334–335, 335f aldosterone laboratory assessment of, 785, 786t, 788f growth disorders and, 338 in patients with cirrhosis and ascites, adefovir dipivoxil, 238 hepatic, 330–331 109 adverse effects of, 403 hepatic features in infancy, 331–332 alemtuzumab, for liver transplantation, duration of therapy, 403 musculoskeletal, 335–336, 336f, 337f 983 and hepatitis B treatment, 402t, neurologic, 338 ALF. See acute liver failure 402–403, 520 ocular, 333–334, 334f Alimentum, 205–208 for HIV hepatitis coinfection, 520 pancreatic, 338–339, 339f alkaline phosphatase (AP), 165–166 resistance to, 403 renal, 333, 334f in cystic fibrosis diagnosis, 585 therapy for transplant patients, 404–405 vascular, 336–338, 338f in sclerosing cholangitis, 461t, 464 use in children, 403 diagnosis of, 328–329, 329t, 330t post-transplantation, 471 adenosine, and blood flow regulation, 899 etiology of, 45–46 ursodeoxycholic acid therapy, 469 adenosine deaminase (ADA) deficiency, 518 genes in, 186 allografts. See liver transplantation adiponectin, in nonalcoholic fatty liver genetics of, 340–342 Alpers’ disease, 812–814, 813f, 824t syndrome, 833 gene identification and mutation acute liver failure and, 74, 77 adolase enzymes and fructose metabolism, analysis, 340 alpha-1,4 glucan-6-glycosyl transferase 603–604 genotype/phenotype correlations, 341 deficiency. See glycogen storage ADPKD. See autosomal dominant Notch signaling pathway, 340–341 disease, type IV polycystic kidney disease testing of, 341–342 5α-cholestan-3β-ol (cholestanol). See adrenal disorders, 907 hypercholesteremia in, 203 cerebrotendinous xanthomatosis Adriamycin (doxorubicin) liver transplantation in, 331 alpha-fetoprotein (AFP) hepatotoxicity of, 487–488 morbidity and mortality rates and and Beckwith–Wiedemann syndrome, for tumor chemotherapy, 965–966 outcome of, 339 944, 946f adult type polycystic disease. See autosomal naming of, 326–327 as indicator of regeneration, 91 dominant polycystic kidney disease and neoplasia, 947f as liver specific marker, 3 aflatoxin and partial biliary diversion for pruritis, for tumors as cause of kwashiorkor, 908 201 diagnosis of, 948–949, 950t in Indian childhood cirrhosis, 649 pathogenesis of, 46 prognosis for, 964 AFP. See alpha-fetoprotein prognosis for, 46 therapy for, 967 agenesis of extrahepatic bile ducts, 58–59 therapy for, 339–340 in tyrosinemia aberrant and accessory, 58, 256 ursodeoxycholic acid, effect on, 194, 201, with carcinoma, 699, 700f anomylies of, 59 339 with chronic liver disease, 698 congenital bronchobiliary fistula, 58–59 alanine aminotransferase (ALT) 12α-hydroxylase deficiency, 750 duplication, 58 and adefovir dipivoxil treatment, 402 α-L-fucosidase protein and gene, 723 hypoplasia, 59 in cirrhosis and chronic liver failure, 107 α-mannosidosis, 716t, 723–724 spontaneous perforation, 59 half-life of, 899 alpha tocopherol. See vitamin E agenesis of the gallbladder, 346 in hepatic drug reaction, 482 α1-antitrypsin deficiency, 545–564 aggresome formation, 558 in hepatitis B infection, 385 cellular adaptive mechanisms to α1-ATZ AGS. See Alagille syndrome in hepatitis C infection, 410 mutations, in ER, 553–555, 554f AhR. See aryl hydrocarbon receptor treatment for persons with normal clinical manifestations of Aicardi-Goutieres syndrome, 241–242 levels, 423 liver disease in, 545–547, 546t, 561f AIDS. See acquired immunodeficiency in hepatitis E infection, 430 lung disease in, 547 syndrome and lamivudine treatment, 401–402 in cystic fibrosis, 579 AIRE1 gene, 451 and liver function tests, 164–165 diagnosis of, 560 ALA-dehydratase porphyria (ADP), in myopathy mimicking liver disease, 907 differential diagnosis of, 546 681–682. See also porphyria(s) and peginterferon treatment, 404 hepatic regeneration and carcinogenesis classification of, 680, 680t in sclerosing cholangitis, 461t, 464 in, 559–560 clinical features of, 681–682 ursodeoxycholic acid therapy, 469 pathogenesis of liver injury in, 555–558, diagnosis of, 682 albendazole 557f drugs that may be harmful in, 682, 683t for ascariasis, 883 pathology of, 557f, 560–561 treatment of, 682 for capillariasis, 883 pathophysiology of, 547–553 Alagille syndrome (AGS), 45–46, 326–342 for Entamoeba histolytica, 882 biosynthesis of α1-antitrypsin, abnormalities associated with, 339 for toxocariasis, 883 551–552 bile duct paucity in, 326–327, 327t albumin clearance and distribution of definitions in, 327f, 327t, 327–328 as carrier for bilirubin, 272, 273f, 282 α1-antitrypsin, 552 histopathology of, 328, 328f hemofiltration of, 90 deficiency of α1-antitrypsin, 549–550 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-85657-7 - Liver Disease in Children, Third Edition Edited by Frederick J. Suchy, Ronald J. Sokol, and William F. Balistreri Index More information I NDEX ■ 997 mechanism for deficiency, 548f, normal concentrations of, 164 anticonvulsants and γ -glutamyltransferase, 552–553 in sclerosing cholangitis, 464 167 structure of α1-antitrypsin, 547–549, and screening for liver damage, 494 antioxidants. See also specific antioxidants 548f, 549f, 550t, 551t and screening for nonalcoholic fatty liver in cystic fibrosis prevention of, 563–564 disease, 830–831, 832, 832t and CFTR function, 579 prognostic factors for, 546 in Wilson’s disease, 642 as future therapy for, 589 treatment of, 561–563 amiodarone and pathogenesis of injury in, 578 alternative strategies
Load more

Recommended publications
  • CYP2A6) by P53
    Transcriptional Regulation of Human Stress Responsive Cytochrome P450 2A6 (CYP2A6) by p53 Hao Hu M.Biotech. (Biotechnology) 2012 The University of Queensland B.B.A. 2009 University of Electronic Science and Technology of China B.Sc. (Pharmacy) 2009 University of Electronic Science and Technology of China A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2016 School of Medicine ABSTRACT Human cytochrome P450 (CYP) 2A6 is highly expressed in the liver and the encoding gene is regulated by various stress activated transcription factors, such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Unlike the other xenobiotic metabolising CYP enzymes (XMEs), CYP2A6 only plays a minor role in xenobiotic metabolism. The CYP2A6 is highly induced by multiple forms of cellular stress conditions, where XMEs expression is normally inhibited. Recent findings suggest that the CYP2A6 plays an important role in regulating BR homeostasis. A computer based sequence analysis on the 3 kb proximate CYP2A6 promoter revealed several putative binding sites for p53, a protein that mediates regulation of antioxidant and apoptosis pathways. In this study, the role of p53 in CYP2A6 gene regulation is demonstrated. The site closest to transcription start site (TSS) is highly homologous with the p53 consensus sequence. The p53 responsiveness of this site was confirmed by transfections with various stepwise deleted of CYP2A6-5’-Luc constructs containing the putative p53RE. Deletion of the putative p53RE resulted in a total abolishment of p53 responsiveness of CYP2A6 promoter. Specific binding of p53 to the putative p53RE was detected by electrophoresis mobility shift assay.
    [Show full text]
  • Characterisation of Bilirubin Metabolic Pathway in Hepatic Mitochondria Siti Nur Fadzilah Muhsain M.Sc
    Characterisation of Bilirubin Metabolic Pathway in Hepatic Mitochondria Siti Nur Fadzilah Muhsain M.Sc. (Medical Research) 2005 Universiti Sains Malaysia Postgrad. Dip. (Toxicology) 2003 University of Surrey B.Sc.(Biomed. Sc.) 2000 Universiti Putra Malaysia A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2014 School of Medicine ABSTRACT Bilirubin (BR), a toxic waste product of degraded haem, is a potent antioxidant at physiological concentrations. To achieve the maximum benefit of BR, its intracellular level needs to be carefully regulated. A system comprising of two enzymes, haem oxygenase-1 (HMOX1) and cytochrome P450 2A5 (CYP2A5) exists in the endoplasmic reticulum (ER), responsible for regulating BR homeostasis. This system is induced in response to oxidative stress. In this thesis, oxidative stress caused accumulation of these enzymes in mitochondria — major producers and targets of reactive oxygen species (ROS) — is demonstrated. To understand the significance of this intracellular targeting, properties of microsomal and mitochondrial BR metabolising enzymes were compared and the capacity of mitochondrial CYP2A5 to oxidise BR in response to oxidative stress is reported. Microsomes and mitochondrial fractions were isolated from liver homogenates of DBA/2J mice, administered with sub-toxic dose of pyrazole, an oxidant stressor. The purity of extracted organelles was determined by analysing the expressions and activities of their respective marker enzymes. HMOX1 and CYP2A5 were significantly increased in microsomes and even more so in mitochondria in response to pyrazole-induced oxidative stress. By contrast, the treatment did not increase either microsomes or mitochondrial Uridine-diphosphate-glucuronosyltransferase 1A1 (UGT1A1), the sole enzyme that catalyses BR elimination through glucuronidation.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Dissertation
    Dissertation Submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the Degree of Doctor of Natural Sciences Presented by Ann-Cathrin Hofer (M.Sc.) Born in Heidelberg, Germany Oral Examination: 12th of September 2016 Regulatory T cells protect the neonatal liver and secure the hepatic circadian rhythm Referees 1st Referee: Prof. Dr. Peter Angel 2nd Referee: Dr. Markus Feuerer This dissertation was performed and written during the period from November 2012 to May 2016 in the German Cancer Research Center (DKFZ) under the supervision of Prof. Dr. Peter Angel and direct supervision of Dr. Markus Feuerer. The dissertation was submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany in June 2016. German Cancer Research Center (DKFZ) Immune Tolerance (D100) Im Neuenheimer Feld 280 69120 Heidelberg, Germany I II Confirmation Hereby, I confirm that I have written this thesis independently, using only the results of my investigation unless otherwise stated. Furthermore, I declare that I have not submitted this thesis for a degree to any other academic or similar institution. Parts of this dissertation have been submitted for publishing: Regulatory T cells protect the liver early in life and safeguard the hepatic circadian rhythm Ann-Cathrin Hofer, Thomas Hielscher, David M. Richards, Michael Delacher, Ulrike Träger, Sophia Föhr, Artyom Vlasov, Marvin Wäsch, Marieke Esser, Annette Kopp-Schneider, Achim Breiling, Frank Lyko, Ursula Klingmüller, Peter Angel, Jakub Abramson, Jeroen Krijgsveld & Markus Feuerer Parts of the experiments in this dissertation were performed in collaboration with other research groups as follows: CG methylation analysis with the 454 pyrosequencing technology: Division of Epigenetics, DKFZ, Heidelberg Dr.
    [Show full text]
  • Neonatal Hyperbilirubinemia
    Clinical Chemistry Trainee Council Pearls of Laboratory Medicine www.traineecouncil.org TITLE: Neonatal Hyperbilirubinemia PRESENTER: Linnea M. Baudhuin, Ph.D., DABMG Slide 1: Title slide Slide 2: Bilirubin is an orange‐yellow pigment derived from the degradation of the heme moiety of hemoproteins, particularly the hemoglobin of mature circulating erythrocytes. Hemo oxygenase is the enzyme initially responsible for the degradation of hemoglobin, producing biliverdin and carbon monoxide. Biliverdin reductase reduces the green‐pigmented biliverdin to bilirubin. Bilirubin production primarily occurs in the liver, but also can occur in the spleen and bone marrow, and as it is produced in the unconjugated form, bilirubin is highly insoluble. Bilirubin is conjugated in the liver, which allows excretion in the bile and urine. Bilirubin is mainly conjugated to glucuronic acid by uridine diphosphate glucuronosyl transferase 1A1, or UGT1A1. Slide 3: Bilirubin is photosensitive because light causes configurational and structural changes to unconjugated bilirubin. The structure of bilirubin, as established by x‐ray crystallography, is a ridge‐tiled configuration stabilized by six intramolecular hydrogen bonds. These six intramolecular hydrogen bonds stabilize the Z‐Z structure of unconjugated bilirubin, rendering it insoluble. Rotation and/or breakage of the bonds on carbon atoms 5 and 15 lead to more open E‐Z‐ and Z‐E‐bilirubin structures, which are more water soluble. The sensitivity of bilirubin to light is the basis for phototherapy in individuals with unconjugated hyperbilirubinemia. Clinical measurement of bilirubin can also be affected due to this light sensitivity. Slide 4: Four fractions of bilirubin can be revealed upon open‐column chromatographic separation that does not involve deproteinization.
    [Show full text]
  • HHC Disorder Setting
    DISORDER/SETTING Question 1: What is the specific clinical disorder to be studied? Question 2: What are the clinical findings defining this disorder? Question 3: What is the clinical setting in which the test is to be performed? Question 4: What DNA test(s) are associated with this disorder? Question 5: Are preliminary screening questions employed? Question 6: Is it a stand-alone test or is it one of a series of tests? Question 7: If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only some tests performed on the basis of other results (series)? ACCE Review of HHC/Adult General Population Disorder/Setting 1-1 Version 2003.6 DISORDER/SETTING Question 1: What is the specific clinical disorder to be studied? The specific clinical disorder is primary iron overload of adult onset sufficient to cause significant morbidity and mortality. • Iron overload refers to excess deposition of iron in parenchymal cells in the liver, pancreas and heart, and/or increased total body mobilizable iron. • Primary refers to a genetically determined abnormality of iron absorption, metabolism, or both. • Morbidity refers to organ damage that results in physical disability over and above that seen in the absence of iron overload. A single inherited disorder, HFE-related hereditary hemochromatosis (HHC) accounts for the vast majority of cases of primary iron overload in Caucasian adults in the United States. The HFE gene is linked to HLA-A on the short arm of chromosome 6. HFE-related HHC is a recessive disorder. A small proportion of primary iron overload cases is explained by inherited disorders other than HFE-related HHC.
    [Show full text]
  • Revisiting Hemochromatosis: Genetic Vs
    731 Review Article on Unresolved Basis Issues in Hepatology Page 1 of 16 Revisiting hemochromatosis: genetic vs. phenotypic manifestations Gregory J. Anderson1^, Edouard Bardou-Jacquet2 1Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute and School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia; 2Liver Disease Department, University of Rennes and French Reference Center for Hemochromatosis and Iron Metabolism Disease, Rennes, France Contributions: (I) Conception and design: Both authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Gregory J. Anderson. Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia. Email: [email protected]. Abstract: Iron overload disorders represent an important class of human diseases. Of the primary iron overload conditions, by far the most common and best studied is HFE-related hemochromatosis, which results from homozygosity for a mutation leading to the C282Y substitution in the HFE protein. This disease is characterized by reduced expression of the iron-regulatory hormone hepcidin, leading to increased dietary iron absorption and iron deposition in multiple tissues including the liver, pancreas, joints, heart and pituitary. The phenotype of HFE-related hemochromatosis is quite variable, with some individuals showing little or no evidence of increased body iron, yet others showing severe iron loading, tissue damage and clinical sequelae. The majority of genetically predisposed individuals show at least some evidence of iron loading (increased transferrin saturation and serum ferritin), but a minority show clinical symptoms and severe consequences are rare.
    [Show full text]
  • Solarbio Catalogue with PRICES
    CAS Name Grade Purity Biochemical Reagent Biochemical Reagent 75621-03-3 C8390-1 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS Ultra Pure Grade 1g 75621-03-3 C8390-5 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS 5g 57-09-0 C8440-25 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 25g 57-09-0 C8440-100 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 100g 57-09-0 C8440-500 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 500g E1170-100 0.5M EDTA (PH8.0) 100ml E1170-500 0.5M EDTA (PH8.0) 500ml 6381-92-6 E8030-100 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 100g 6381-92-6 E8030-500 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 500g 6381-92-6 E8030-1000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 1kg 6381-92-6 E8030-5000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 5kg 60-00-4 E8040-100 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 100g 60-00-4 E8040-500 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 500g 60-00-4 E8040-1000 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 1kg 67-42-5 E8050-5 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 5g 67-42-5 E8050-10 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 10g 50-01-1 G8070-100 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 100g 50-01-1 G8070-500 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 500g 56-81-5
    [Show full text]
  • 1 Molecular Physiology and Pathophysiology of Bilirubin Handling by the Blood, Liver
    1 1 MOLECULAR PHYSIOLOGY AND PATHOPHYSIOLOGY OF BILIRUBIN HANDLING BY THE BLOOD, LIVER, 2 INTESTINE, AND BRAIN IN THE NEWBORN 3 THOR W.R. HANSEN1, RONALD J. WONG2, DAVID K. STEVENSON2 4 1Division of Paediatric and Adolescent Medicine, Institute of Clinical Medicine, Faculty of Medicine, 5 University of Oslo, Norway 6 2Department of Pediatrics, Stanford University School of Medicine, Stanford CA, USA 7 __________________________________________________________________________________ 8 2 9 I. Introduction 10 II. Bilirubin in the Body 11 A. Bilirubin Chemistry 12 1. Bilirubin structure 13 2. Bilirubin solubility 14 3. Bilirubin isomers 15 4. Heme degradation 16 5. Biliverdin and biliverdin reductase (BVR) 17 B. Bilirubin as an Antioxidant 18 C. Bilirubin as a Toxin 19 1. Bilirubin effects on enzyme activity 20 2. Toxicity of bilirubin conjugates and isomers 21 D. Other Functions/Roles 22 1. Drug displacement by bilirubin 23 2. Bilirubin interactions with the immune system and 24 inflammatory/infectious mechanisms 25 III. The Production of Bilirubin in the Body 26 A. Heme Catabolism and Its Regulation 27 1. Genetic variants in bilirubin production 28 B. The Effect of Hemolysis 29 1. Disorders associated with increased bilirubin production 30 IV. Bilirubin Binding and Transport in Blood 31 V. Bilirubin in the Liver 32 A. Hepatocellular Uptake and Intracellular Processing 33 B. Bilirubin Conjugation 34 1. Genetic variants in bilirubin conjugation 3 35 a. Crigler-Najjar syndrome type I 36 b. Crigler-Najjar syndrome type II 37 c. Gilbert syndrome 38 2. Genetic variants in transporter proteins 39 C. Bilirubin Excretion 40 VI. Bilirubin in the Intestines 41 A.
    [Show full text]
  • Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems Supramolecular Chemistry of Biomimetic Systems Junbai Li Editor
    Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems Supramolecular Chemistry of Biomimetic Systems Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems 123 Editor Junbai Li Institute of Chemistry, Chinese Academy of Sciences Beijing China ISBN 978-981-10-6058-8 ISBN 978-981-10-6059-5 (eBook) DOI 10.1007/978-981-10-6059-5 Library of Congress Control Number: 2017949116 © Springer Nature Singapore Pte Ltd. 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd.
    [Show full text]
  • OR09-1 Neonatal Exendin-4 Normalizes Epigenetic Modifications at the Proximal Promoter of PGC1-Α in IUGR Rat Liver
    ENDO 2010 Abstract OR09-1 Neonatal Exendin-4 Normalizes Epigenetic Modifications at the Proximal Promoter of PGC1-α in IUGR Rat Liver. SE Pinney MD1, Y Han MD1 and RA Simmons MD1. 1Children's Hosp Philadelphia, Univ Pennsylvania Sch of Med Philadelphia, PA. Intrauterine growth retardation (IUGR) has been linked to the development of type 2 diabetes in adults. IUGR impairs hepatic mitochondrial function in prediabetic IUGR animals. PGC1-a is a transcriptional coactivator and metabolic regulator that promotes mitochondrial biogenesis and is critical for normal mitochondrial function. Expression is decreased in IUGR liver. Exendin-4 (Ex4), a long-acting agonist of the glucose dependent insulinotropic hormone (GLP-1), improves mitochondria function, normalizes hepatic insulin resistance, and prevents diabetes in the IUGR rat. The objectives were to determine if Ex4 normalizes PGC1- α expression; and whether changes in expression are linked to epigenetic modifications at the PGC1- α promoter. IUGR newborn pups were treated with a 6-day course (day 1-6) of Ex4 and liver was harvested for analyses at 8 weeks of age. Gene expression was measured by quantitative (q)-PCR. Histone modifications were evaluated by chromatin immunoprecipitation assays and q-PCR. PGC1- α gene expression was decreased in adult IUGR animals compared to control by 80% (p=0.017) and Ex4 treatment normalized PGC1-expression to levels equivalent to controls (p=0.36). Similarly, mitochondrial DNA and protein content were significantly reduced in IUGR liver (62±4.2% of controls, p=0.012) and neonatal Ex4 treatment normalized mitochondria content (102±4.6% of controls, p=0.45).
    [Show full text]
  • Inherited Disorders of Bilirubin Clearance N
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2015 Inherited disorders of bilirubin clearance N. Memon B. I. Weinberger Zucker School of Medicine at Hofstra/Northwell T. Hegyi L. M. Aleksunes Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Pediatrics Commons Recommended Citation Memon N, Weinberger B, Hegyi T, Aleksunes L. Inherited disorders of bilirubin clearance. 2015 Jan 01; 79(3):Article 2776 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/2776. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pediatr Manuscript Author Res. Author manuscript; Manuscript Author available in PMC 2016 April 05. Published in final edited form as: Pediatr Res. 2016 March ; 79(3): 378–386. doi:10.1038/pr.2015.247. Inherited Disorders of Bilirubin Clearance Naureen Memon1,*, Barry I Weinberger2, Thomas Hegyi1, and Lauren M Aleksunes3 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 2Department of Pediatrics, Cohen Children’s Medical Center of New York, New Hyde Park, NY, USA 3Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ, USA Abstract Inherited disorders of hyperbilirubinemia may be caused by increased bilirubin production or decreased bilirubin clearance.
    [Show full text]